Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: After-Hours Movers » 19:02
07/09/20
07/09
19:02
07/09/20
19:02
SLP

Simulations Plus

$63.55 /

+1.57 (+2.53%)

, PSMT

PriceSmart

$60.38 /

+0.895 (+1.50%)

, MATX

Matson

$27.46 /

-0.69 (-2.45%)

, ZIOP

Ziopharm

$3.24 /

+0.04 (+1.25%)

, IART

Integra LifeSciences

$46.22 /

-0.555 (-1.19%)

, WDFC

WD-40

$200.59 /

-2.48 (-1.22%)

, FC

Franklin Covey

$19.18 /

-1.125 (-5.54%)

, KERN

Akerna

$7.25 /

-0.21 (-2.82%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

WDFC WD-40
$200.59 /

-2.48 (-1.22%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

PSMT PriceSmart
$60.38 /

+0.895 (+1.50%)

MATX Matson
$27.46 /

-0.69 (-2.45%)

KERN Akerna
$7.25 /

-0.21 (-2.82%)

IART Integra LifeSciences
$46.22 /

-0.555 (-1.19%)

FC Franklin Covey
$19.18 /

-1.125 (-5.54%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

06/08/20 Craig-Hallum
Simulations Plus price target raised to $56 from $40 at Craig-Hallum
01/06/20 Craig-Hallum
Simulations Plus initiated with a Buy at Craig-Hallum
PSMT PriceSmart
$60.38 /

+0.895 (+1.50%)

05/08/20 Scotiabank
Scotiabank downgrades PriceSmart amid COVID-19 restrictions
05/08/20 Scotiabank
PriceSmart downgraded to Sector Perform from Outperform at Scotiabank
09/23/19 Kansas City Capital
PriceSmart downgraded to Perform from Outperform at Kansas City Capital
07/18/19
Fly Intel: Top five analyst upgrades
MATX Matson
$27.46 /

-0.69 (-2.45%)

04/06/20 Stephens
Matson downgraded to Equal Weight from Overweight at Stephens
02/27/20 Stifel
Matson upgraded to Buy from Hold at Stifel
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
IART Integra LifeSciences
$46.22 /

-0.555 (-1.19%)

05/27/20
Fly Intel: Top five analyst initiations
05/27/20 Citi
Integra LifeSciences initiated with a Neutral at Citi
05/21/20 Piper Sandler
Early diligence on new Tactile Systems CEO very positive, says Piper Sandler
05/08/20 JMP Securities
Integra LifeSciences price target lowered to $65 from $75 at JMP Securities
WDFC WD-40
$200.59 /

-2.48 (-1.22%)

03/27/20 DA Davidson
WD-40 upgraded to Buy from Neutral at DA Davidson
03/27/20 DA Davidson
WD-40 upgraded to Buy from Neutral at DA Davidson
01/07/20 DA Davidson
WD-40 downgraded to Neutral from Buy at DA Davidson
01/07/20 DA Davidson
WD-40 downgraded to Neutral from Buy at DA Davidson
FC Franklin Covey
$19.18 /

-1.125 (-5.54%)

04/03/20 Roth Capital
Franklin Covey price target lowered to $28 from $51 at Roth Capital
03/30/20 B. Riley FBR
Franklin Covey price target lowered to $32 from $45 at B. Riley FBR
01/30/20
Franklin Covey management to meet with Roth Capital
KERN Akerna
$7.25 /

-0.21 (-2.82%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

WDFC WD-40
$200.59 /

-2.48 (-1.22%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

PSMT PriceSmart
$60.38 /

+0.895 (+1.50%)

MATX Matson
$27.46 /

-0.69 (-2.45%)

KERN Akerna
$7.25 /

-0.21 (-2.82%)

IART Integra LifeSciences
$46.22 /

-0.555 (-1.19%)

FC Franklin Covey
$19.18 /

-1.125 (-5.54%)

  • 05
    Feb
WDFC WD-40
$200.59 /

-2.48 (-1.22%)

WDFC WD-40
$200.59 /

-2.48 (-1.22%)

PSMT PriceSmart
$60.38 /

+0.895 (+1.50%)

KERN Akerna
$7.25 /

-0.21 (-2.82%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

WDFC WD-40
$200.59 /

-2.48 (-1.22%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

PSMT PriceSmart
$60.38 /

+0.895 (+1.50%)

KERN Akerna
$7.25 /

-0.21 (-2.82%)

FC Franklin Covey
$19.18 /

-1.125 (-5.54%)

Conference/Events
Cantor Fitzgerald pharmaceuticals analysts hold analyst/industry conference call » 17:06
07/09/20
07/09
17:06
07/09/20
17:06
CLDX

Celldex

$12.37 /

+0.21 (+1.73%)

Pharmaceuticals Analysts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CLDX Celldex
$12.37 /

+0.21 (+1.73%)

CLDX Celldex
$12.37 /

+0.21 (+1.73%)

07/01/20 Cantor Fitzgerald
Celldex price target raised to $18 from $12 at Cantor Fitzgerald
06/12/20 Cantor Fitzgerald
Celldex price target raised to $12 from $8 at Cantor Fitzgerald
02/21/20
Fly Intel: Top five analyst initiations
02/20/20 Cantor Fitzgerald
Celldex initiated with an Overweight at Cantor Fitzgerald
CLDX Celldex
$12.37 /

+0.21 (+1.73%)

  • 16
    Jun
CLDX Celldex
$12.37 /

+0.21 (+1.73%)

Hot Stocks
Ziopharm initiates Phase 1 trial evaluating CD19-specific CAR-T » 16:16
07/09/20
07/09
16:16
07/09/20
16:16
ZIOP

Ziopharm

$3.24 /

+0.04 (+1.25%)

Ziopharm Oncology…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

  • 05
    Feb
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

Yesterday
Hot Stocks
Ziopharm doses first patient with DIPG in Ad-RTS-hIL-12 study » 08:42
07/08/20
07/08
08:42
07/08/20
08:42
ZIOP

Ziopharm

$3.22 /

+ (+0.00%)

Ziopharm announced that…

Ziopharm announced that the first patient with diffuse intrinsic pontine glioma, or DIPG, has been dosed in its phase 1/2 study of Ad-RTS-hIL-12 with veledimex for the treatment of pediatric brain tumors.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.22 /

+ (+0.00%)

ZIOP Ziopharm
$3.22 /

+ (+0.00%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
ZIOP Ziopharm
$3.22 /

+ (+0.00%)

  • 05
    Feb
ZIOP Ziopharm
$3.22 /

+ (+0.00%)

Over a week ago
Recommendations
Celldex price target raised to $18 from $12 at Cantor Fitzgerald » 06:45
07/01/20
07/01
06:45
07/01/20
06:45
CLDX

Celldex

$12.96 /

+0.42 (+3.35%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Kristen Kluska raised the firm's price target on Celldex to $18 from $12 and keeps an Overweight rating on the shares after the company provided additional information about next steps to its program that was announced at EAACI earlier this month. Celldex announced plans to run Phase 1b studies in chronic inducible urticaria and chronic spontaneous urticaria this fall, with results potentially expected in 1Q21 and 2H21, respectively, and could bring a subQ formulation of CDX-0159 to studies during 3Q20. Additionally, Kluska spoke to three physicians regarding their views on the safety and efficacy data and the chronic urticaria treatment landscape, saying general sentiment is that CDX-0159 has a differentiated mechanism of action and clearly works on mast cells.

ShowHide Related Items >><<
CLDX Celldex
$12.96 /

+0.42 (+3.35%)

CLDX Celldex
$12.96 /

+0.42 (+3.35%)

06/12/20 Cantor Fitzgerald
Celldex price target raised to $12 from $8 at Cantor Fitzgerald
02/21/20
Fly Intel: Top five analyst initiations
02/20/20 Cantor Fitzgerald
Celldex initiated with an Overweight at Cantor Fitzgerald
CLDX Celldex
$12.96 /

+0.42 (+3.35%)

  • 16
    Jun
CLDX Celldex
$12.96 /

+0.42 (+3.35%)

Options
Unusual call flow in option market yesterday » 07:35
06/24/20
06/24
07:35
06/24/20
07:35
AAPL

Apple

$366.23 /

+7.15 (+1.99%)

, ETSY

Etsy

$101.31 /

+5.09 (+5.29%)

, ZIOP

Ziopharm

$3.57 /

+0.015 (+0.42%)

Notable call activity was…

Notable call activity was cited Tuesday in Apple (AAPL), Etsy (ETSY), and Ziopharm (ZIOP).

ShowHide Related Items >><<
ZIOP Ziopharm
$3.57 /

+0.015 (+0.42%)

ETSY Etsy
$101.31 /

+5.09 (+5.29%)

AAPL Apple
$366.23 /

+7.15 (+1.99%)

AAPL Apple
$366.23 /

+7.15 (+1.99%)

06/24/20 BMO Capital
Criteo downgraded to Market Perform from Outperform at BMO Capital
06/23/20 Baird
Apple price target raised to $390 from $320 at Baird
06/23/20 Credit Suisse
Apple launches at WWDC more incremental than thesis-changing, says Credit Suisse
06/23/20 Oppenheimer
Apple creating 'wide moat' for own ecosystem, says Oppenheimer
ETSY Etsy
$101.31 /

+5.09 (+5.29%)

06/23/20 RBC Capital
Etsy price target raised to $117 from $79 at RBC Capital
06/22/20 Goldman Sachs
Etsy price target raised to $120 from $88 at Goldman Sachs
06/10/20
Fly Intel: Top five analyst upgrades
06/10/20 Jefferies
Etsy upgraded to Buy from Hold at Jefferies
ZIOP Ziopharm
$3.57 /

+0.015 (+0.42%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
ZIOP Ziopharm
$3.57 /

+0.015 (+0.42%)

ETSY Etsy
$101.31 /

+5.09 (+5.29%)

AAPL Apple
$366.23 /

+7.15 (+1.99%)

ETSY Etsy
$101.31 /

+5.09 (+5.29%)

AAPL Apple
$366.23 /

+7.15 (+1.99%)

ETSY Etsy
$101.31 /

+5.09 (+5.29%)

AAPL Apple
$366.23 /

+7.15 (+1.99%)

ZIOP Ziopharm
$3.57 /

+0.015 (+0.42%)

ETSY Etsy
$101.31 /

+5.09 (+5.29%)

AAPL Apple
$366.23 /

+7.15 (+1.99%)

AAPL Apple
$366.23 /

+7.15 (+1.99%)

Options
Calls lead puts 11:1 in Ziopharm Oncology » 10:10
06/23/20
06/23
10:10
06/23/20
10:10
ZIOP

Ziopharm

$3.64 /

+0.08 (+2.25%)

Calls lead puts 11:1 in…

Calls lead puts 11:1 in Ziopharm Oncology. Shares up 10c, or nearly 3%, to $3.66 this morning with 1400 calls trading early, vs 120 puts and July 4 calls seeing most of the flow, including a 15c buyer of 522, followed by 20c for another 500.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.64 /

+0.08 (+2.25%)

ZIOP Ziopharm
$3.64 /

+0.08 (+2.25%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
ZIOP Ziopharm
$3.64 /

+0.08 (+2.25%)

ZIOP Ziopharm
$3.64 /

+0.08 (+2.25%)

Hot Stocks
Ziopharm completes enrollment of Phase 2 trial of IL-12 with Libtayo » 08:32
06/22/20
06/22
08:32
06/22/20
08:32
ZIOP

Ziopharm

$3.34 /

+0.06 (+1.83%)

Ziopharm Oncology (ZIOP)…

Ziopharm Oncology (ZIOP) announced that 36 subjects have been enrolled in the phase 2 clinical trial evaluating Ad-RTS-hIL-12 with veledimex in combination with the PD-1 inhibitor Libtayo for the treatment of recurrent or progressive glioblastoma in adults. Subjects in this multi-center trial were enrolled from seven hospitals specializing in the treatment of brain cancers across the United States. Ziopharm's Controlled IL-12 platform is an investigational gene therapy designed to induce and control the production of human interleukin 12, a master-regulator of the immune system. In the setting of rGBM, the Company is leveraging the anti-tumor effects for Controlled IL-12 as a monotherapy and in combination with PD-1 inhibitors. Clinical data supporting the combination of Controlled IL-12 and a PD-1 inhibitor were initially published in Science Translational Medicine. Data from serial biopsies in patients with rGBM revealed that Controlled IL-12 results in the sustained influx of activated T cells and upregulation of PD-1 expression, providing a compelling rationale for this combination. Recently, additional data from a phase 1 trial were presented at the American Society of Clinical Oncology 2020 virtual meeting showing Controlled IL-12 in combination with a PD-1 inhibitor had a favorable safety profile and preliminary signs of anti-tumor efficacy. The open-label, single-arm phase 2 trial is designed to examine Controlled IL-12 in combination with cemiplimab in 36 patients with rGBM, with the primary endpoints being safety and efficacy. Patients with rGBM scheduled for resection, who have not been treated previously with immune checkpoint inhibitors, received Ad-RTS-hIL-12 intratumorally at the time of surgical resection plus 20 mg of veledimex, an oral activator of Ad-RTS-hIL-12, daily for 14 days. Patients will also receive cemiplimab intravenously every three weeks until documented progression or withdrawal from the study. Trial investigators may enroll additional patients currently in screening. In November 2018, Ziopharm and Regeneron entered a clinical supply agreement to evaluate combination therapy of Ziopharm's Controlled IL-12 with Regeneron's (REGN) PD-1 antibody cemiplimab to treat patients with rGBM.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.34 /

+0.06 (+1.83%)

ZIOP Ziopharm
$3.34 /

+0.06 (+1.83%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
ZIOP Ziopharm
$3.34 /

+0.06 (+1.83%)

ZIOP Ziopharm
$3.34 /

+0.06 (+1.83%)

Hot Stocks
RTW Investments reports 9.95% passive stake in Celldex  10:39
06/19/20
06/19
10:39
06/19/20
10:39
CLDX

Celldex

$11.19 /

+0.81 (+7.80%)

 
ShowHide Related Items >><<
CLDX Celldex
$11.19 /

+0.81 (+7.80%)

CLDX Celldex
$11.19 /

+0.81 (+7.80%)

06/12/20 Cantor Fitzgerald
Celldex price target raised to $12 from $8 at Cantor Fitzgerald
02/21/20
Fly Intel: Top five analyst initiations
02/20/20 Cantor Fitzgerald
Celldex initiated with an Overweight at Cantor Fitzgerald
CLDX Celldex
$11.19 /

+0.81 (+7.80%)

  • 16
    Jun
CLDX Celldex
$11.19 /

+0.81 (+7.80%)

Initiation
Ziopharm initiated with a Buy at Jefferies » 06:00
06/19/20
06/19
06:00
06/19/20
06:00
ZIOP

Ziopharm

$3.28 /

+0.04 (+1.23%)

Jefferies analyst Chris…

Jefferies analyst Chris Howerton initiated coverage of Ziopharm Oncology with a Buy rating and $7 price target. While the company has a long history, it has a "new story with exciting" gene and cellular therapies for oncology, Howerton tells investors in a research note. The analyst sees "substantial upside" from clinical success in either of Ziopharm's programs, TCR-T in solid tumors and Ad-RTS-hIL12 in recurrent glioblastoma.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.28 /

+0.04 (+1.23%)

ZIOP Ziopharm
$3.28 /

+0.04 (+1.23%)

05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
03/03/20 Cantor Fitzgerald
Ziopharm initiated with an Overweight at Cantor Fitzgerald
ZIOP Ziopharm
$3.28 /

+0.04 (+1.23%)

ZIOP Ziopharm
$3.28 /

+0.04 (+1.23%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.